论文部分内容阅读
目的:分析131I治疗Graves病甲亢的早期疗效及其早发甲低影响因素。方法:对接受131I治疗的69例Graves病甲亢患者随访1a,根据是否发生甲低分为第1组(甲低组)与第2组(无甲低组),采用SPSS统计软件分析年龄、性别、病程、治疗前甲状腺质量、计划给予每克甲状腺组织的摄取剂量、131I剂量、治疗前后甲状腺功能、是否接受过内科药物治疗等因素与甲低的关系。结果:治疗后1a,有18.9%(13/69例)患者发生甲低,有81.1%(56/69例)患者甲状腺功能恢复正常,两组的131I剂量间差异无显著性(t=1.069,P>0.05),但每克组织给予的摄取剂量间差异有显著性(t=2.696,P<0.05)。结论:早发甲低与甲状腺质量及给予的每克组织实际摄取131I剂量有关,只要131I治疗前停用内科药物治疗适当时间,131I疗效不受影响。
Objective: To analyze the early curative effect of 131I on Graves’ disease and its influential factors of early hypothyroidism. Methods: Ninety-nine patients with Graves disease and hyperthyroidism undergoing 131I were followed up for 1 year. According to whether hypothyroidism occurred in group 1 (hypothyroidism group) and group 2 (hypothyroidism group), SPSS statistical software was used to analyze the age and gender , Course of disease, pre-treatment thyroid mass, planned dose per gram of thyroid tissue taken, 131I dose, thyroid function before and after treatment, whether received medical treatment and other factors and hypothyroidism. Results: After treatment, 18.9% (13/69) patients developed hypothyroidism and 81.1% (56/69 patients) returned to normal thyroid function. There was no significant difference between the two groups in the 131I dose (t = 1.069, P> 0.05). However, there was a significant difference between the doses administered per gram of tissue (t = 2.696, P <0.05). CONCLUSIONS: Early onset hypothyroidism correlates with thyroid mass and the actual dose of 131 I administered per gram of tissue, as long as the appropriate medical treatment is discontinued before 131 I treatment, the efficacy of 131 I is unaffected.